• Potential Liability and Regulatory Impact

    Monday April 22, 2013

    Amgen, Inc., a California-based biotechnology company, has agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act for marketing Aranesp to treat anemia in nursing home residents.  Aranesp may be indicated in residents who have anemia associated with conditions such as renal failure, dialysis or chemotherapy but not necessarily anemia from other causes.  The government alleged that Amgen distributed materials to consultant pharmacists and nursing home staff encouraging the use of Aranesp for patients who did not have anemia associated with chronic renal failure. 


    Please see the attached release from the U. S. Department of Justice for additional details.

    US Department of Justice - Marketing Aranesp in Nursing Homes


    Categories :


Comments closed